SPC25 Activates the Warburg Effect to Inhibit Ferroptosis in Prostate Cancer Cells

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• SPC25 is linked to poor outcomes in cancers, but its function in prostate cancer (PRAD) remains unknown.
• Prostate cancer research needs further investigation into glycolysis and ferroptosis pathways.

Purpose of the Study:

• To investigate the role of SPC25 in prostate cancer (PRAD).
• To explore the relationship between SPC25, glycolysis, and ferroptosis in PRAD.

Main Methods:

• Bioinformatics analysis, quantitative polymerase chain reaction (qPCR), and Western blot were used to assess SPC25 expression and its correlations.
• Cell viability, ferroptosis assays (Fe2+, MDA), and glycolysis assays (glucose uptake, lactate, Seahorse XF) were performed.
• Gene Set Enrichment Analysis (GSEA) identified enriched pathways related to SPC25.

Main Results:

• SPC25 was significantly upregulated in PRAD tissues and cells, correlating with adverse outcomes.
• SPC25 overexpression enhanced cancer cell vitality, increased glycolysis (glucose uptake, lactate secretion), and suppressed ferroptosis markers (Fe2+, MDA).
• 2-deoxy-d-glucose (2-DG) counteracted SPC25's effects on glycolysis and ferroptosis.

Conclusions:

• SPC25 promotes prostate cancer progression by upregulating glycolysis, which in turn inhibits ferroptosis.
• Targeting SPC25 or modulating glycolysis may offer novel therapeutic strategies for PRAD.